SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from CT388-103, a Phase

A once-weekly subcutaneous injection of CT-388 achieved a statistically significant placebo-adjusted weight loss of 22.5% (p < 0.001) at 48 weeks at the highest dose

Cipla’s incoming MD and CEO-designate, Achin Gupta, outlined a two-to-three-year strategy focusing on deepening the domestic market presence and pursuing selective inorganic growth and innovation.

Roche”s experimental obesity drug delivers positive phase II results (www.reuters.com) 15:03  

A recent study highlights a surprising potential benefit of diabetes and obesity drugs, GLP-1 receptor agonists, in improving overall health and possibly extending survival in

A larger percentage of GLP-1 users say social media and online research are their most trusted source for microdosing information over their clinician. Medscape Medical

Abstract Aim Heart failure with preserved ejection fraction (HFpEF) presents a therapeutic challenge, characterised by a paucity of validated treatments. Emerging data suggest that targeting

CHILD star Amanda Bynes looks slimmer than ever in a new video after revealing she has been using weight loss jabs. At the end of

In today’s CEO Daily: Fortune Editor-in-Chief Alyson Shontell interviews Pfizer CEO Albert Bourla. The big story: Target’s incoming CEO speaks out about the immigration crackdown

As doctors learn why GLP-1s don’t work for about 50% of people, they are also learning more about the complex drivers of obesity. They foresee

Roche’s dual GLP-1/GIP receptor agonist has been tied to 22.5% weight loss at 48 weeks, validating the company’s decision to move the asset into phase

As GLP-1 adoption accelerates across the Middle East, Havas brings a unique specialized strategic cultural lens to the rapidly evolving metabolic economy

SAN FRANCISCO–(BUSINESS WIRE)– #SUD–Baseline Therapeutics, Inc. (“Baseline”), a clinical-stage biotechnology company developing addiction therapeutics, today announced the launch of the company to advance a new

Gene therapy for weight loss is being explored as a potential game-changer, with therapy aiming to program the body to produce its own GLP-1 hormone

This randomized controlled trial shows that structured moderate-to-vigorous exercise, alone or combined with liraglutide, improves physical function and cardiorespiratory fitness after diet-induced weight loss in

As GLP-1 pills for weight loss enter the U.S. market, some pharmaceutical companies are testing the possibility of a gene therapy to stimulate GLP-1 production,

(MedPage Today) — Postmenopausal women on the GLP-1 medication tirzepatide (Zepbound) for obesity lost more weight if they were also using menopause hormone therapy, a

Diabetes Mellitus (DM) is a rapidly increasing disease around the world. It is known that DM is associated with numerous complications which affect life quality

A South Carolina drug company has launched a proposed class action against major pharmaceutical company Novo Nordisk, alleging it engaged in anticompetitive behavior to prolong

This content was created by Hive Labs in partnership with Fairfax Partners on behalf of LIR Life Sciences Corp. Treating obesity isn’t always as simple

According to doctors, making a misstep is easier than you may think.

Developed by board-certified endocrinologist Dr. Eiriny Eskander, Caloria delivers physician-backed insights for people managing GLP-1 use, diabetes, PCOS, and menopause. LOS ANGELES, Jan. 26, 2026

Post Content

Danish national registry data suggest adults with type 2 diabetes taking SGLT2 inhibitors have a slightly lower risk of developing diabetic foot problems than those

Once known for bottomless breadsticks and supersized meals, American chain restaurants are increasingly rethinking their portion sizes. As GLP-1 weight-loss medications like Ozempic, Wegovy and

Abstract Background Parkinson’s disease (PD) is an increasingly prevalent neurodegenerative condition, particularly among individuals with type 2 diabetes mellitus (T2DM). While prior studies have suggested

Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the best US stocks to buy under $50. On January 12, Viking Therapeutics, Inc. (NASDAQ:VKTX) announced a significant

As GLP-1 drugs become more available, some people might use them despite not having excess weight.

US biotech firm Fractyl Health is developing Rejuva, an experimental gene therapy that aims to trigger long-term weight loss by programming the pancreas to produce

World-leading gut health expert PROFESSOR TIM SPECTOR reveals brand new research around why dementia, depression, and anxiety may start in the gut, how flossing lowers

This editorial argues that GLP-1 receptor agonists could substantially improve healthspan and reduce premature mortality in people with serious mental illnesses by targeting cardiometabolic risk

(MedPage Today) — LAS VEGAS — GLP-1-based therapies may offer benefits in inflammatory bowel disease (IBD) that extend beyond their metabolic indication, according to two

Engineering of marker-free lettuce chloroplast genome to express CTB-Exenatide and CTB-Lixisenatide for oral delivery. Upper panel: Chemically synthesised exenatide or lixisenatide require expensive production, purification,

Five ways weight-loss jabs are changing spending habits  BBC Smaller portions, more protein: How GLP-1s are quietly changing chain restaurant menus  NBC News Gut-friendly foods: GLP-1 drives